hypothesis,evidences,label
There were only 3 adverse events in NCT00894504 which occurred more than twice.,"[""Adverse Events 1:"", ""  Total: 10/71 (14.08%)"", ""  ATRIAL FIBRILLATION 1/71 (1.41%)"", ""  CARDIAC TAMPONADE 1/71 (1.41%)"", ""  PERICARDIAL EFFUSION 1/71 (1.41%)"", ""  SUPRAVENTRICULAR TACHYCARDIA 1/71 (1.41%)"", ""  DIARRHOEA 1/71 (1.41%)"", ""  NAUSEA 1/71 (1.41%)"", ""  VOMITING 1/71 (1.41%)"", ""  CHEST PAIN 1/71 (1.41%)"", ""  PNEUMONIA 1/71 (1.41%)"", ""  MALIGNANT PLEURAL EFFUSION 1/71 (1.41%)"", ""  HEPATIC ENCEPHALOPATHY 1/71 (1.41%)""]",Contradiction
"compared to cohort 1 of NCT00475670, there are more cases of every observed adverse event in cohort 2. ","[""Adverse Events 1:"", ""  Total: 0/3 (0.00%)"", ""  Febrile Neutropenia * 0/3 (0.00%)"", ""  Neutropenia * 0/3 (0.00%)"", ""  Sudden Death * 0/3 (0.00%)"", ""  Bacterial Infection * 0/3 (0.00%)"", ""  Bronchitis * 0/3 (0.00%)"", ""  Sepsis * 0/3 (0.00%)"", ""  Lymphoedema * 0/3 (0.00%)"", ""Adverse Events 2:"", ""  Total: 6/41 (14.63%)"", ""  Febrile Neutropenia * 1/41 (2.44%)"", ""  Neutropenia * 1/41 (2.44%)"", ""  Sudden Death * 1/41 (2.44%)"", ""  Bacterial Infection * 1/41 (2.44%)"", ""  Bronchitis * 1/41 (2.44%)"", ""  Sepsis * 1/41 (2.44%)"", ""  Lymphoedema * 1/41 (2.44%)""]",Entailment
There were 0 observed cases of Tibia or Fibula fractures in NCT01752907 or NCT01940497.,"[""Adverse Events 1:"", ""  Total: 16/149 (10.74%)"", ""  Anaemia 0/149 (0.00%)"", ""  Febrile neutropenia 7/149 (4.70%)"", ""  Neutropenia 1/149 (0.67%)"", ""  Pancytopenia 1/149 (0.67%)"", ""  Atrial fibrillation 2/149 (1.34%)"", ""  Cardiac failure congestive 0/149 (0.00%)"", ""  Abdominal pain 0/149 (0.00%)"", ""  Diarrhoea 2/149 (1.34%)"", ""  Dyspepsia 0/149 (0.00%)"", ""  Gastritis haemorrhagic 0/149 (0.00%)"", ""  Nausea 2/149 (1.34%)"", ""Adverse Events 2:"", ""  Total: 20/151 (13.25%)"", ""  Anaemia 1/151 (0.66%)"", ""  Febrile neutropenia 4/151 (2.65%)"", ""  Neutropenia 2/151 (1.32%)"", ""  Pancytopenia 0/151 (0.00%)"", ""  Atrial fibrillation 0/151 (0.00%)"", ""  Cardiac failure congestive 1/151 (0.66%)"", ""  Abdominal pain 1/151 (0.66%)"", ""  Diarrhoea 3/151 (1.99%)"", ""  Dyspepsia 1/151 (0.66%)"", ""  Gastritis haemorrhagic 1/151 (0.66%)"", ""  Nausea 1/151 (0.66%)""]",Contradiction
There 55 more Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) in cohort 2 of NCT00370552 than in cohort 1.,"[""Outcome Measurement: "", ""  Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) While On-study"", ""  CR=Disappearance of all clinical and radiologic evidence of target lesions; PR=At least 30% reduction in the sum of the longest diameter of all target lesions."", ""  Time frame: Baseline visit and then every 8 weeks to 12 months, then every 3 months until disease progression"", ""Results 1: "", ""  Arm/Group Title: Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg"", ""  Arm/Group Description: Ixabepilone,16 mg/m^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered after ixabepilone as IV infusion every 2 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity."", ""  Overall Number of Participants Analyzed: 46"", ""  Measure Type: Number"", ""  Unit of Measure: Percentage of participants  47.8        (32.9 to 63.1)"", ""Results 2: "", ""  Arm/Group Title: Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg"", ""  Arm/Group Description: Ixabepilone, 40 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity After Cycle 4, dose reduction to 32 mg/m^2 implemented for all subsequent cycles. Bevacizumab, 15 mg/kg, administered after ixabepilone as IV infusion every 3 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity."", ""  Overall Number of Participants Analyzed: 45"", ""  Measure Type: Number"", ""  Unit of Measure: Percentage of participants  71.1        (55.7 to 83.6)""]",Contradiction
Women classified as high-risk of developing breast cancer within the next 5 years and within her lifetime by the Gail model are eligible for NCT00853996.,"[""Inclusion Criteria:"", ""  Gail risk >= 1.7% and/or relative risk >= 3 times that for 5-year age group""]",Entailment
"Patients have received prior radiation treatment, to treat the current breast cancer, in the last two 2 weeks before study entry are eligible for NCT00297596 but excluded from NCT00580333.","[""Inclusion Criteria:"", ""  Patients may have received one prior trastuzumab/chemotherapy containing regimen or prior single agent trastuzumab."", ""  All prior chemotherapy, trastuzumab and radiation therapy should be completed > 2 weeks before enrollment.""]",Contradiction
Patients prescribed with bisoprolol or labetalol to treat atrial fibrillation are excluded from NCT00821886.,"[""Exclusion Criteria:"", ""  current use of medications (e.g., digitalis, beta-blockers, calcium channel-blockers) that alter cardiac conduction, if these medications are administered for the management of cardiac arrhythmia, angina, or CHF. If these medications are administered for other reasons (e.g., hypertension), the patient may be eligible.""]",Entailment
"A total of 7 patients in NCT00444587 were observed with either Leukopenia, Cardiopulmonary failure or Diarrhoea.","[""  Leukopenia 2/93 (2.15%)"", ""  Cardiopulmonary failure 2/93 (2.15%)"", ""  Diarrhoea 3/93 (3.23%)""]",Entailment
Cohort 1 of NCT00856492 recorded no deaths and no cases of Anemia.,"[""Adverse Events 1:"", ""  Total: 22/96 (22.92%)"", ""  Anemia  1/96 (1.04%)"", ""  Febrile neutropenia  4/96 (4.17%)"", ""  Heart failure  1/96 (1.04%)"", ""  Abdominal pain  1/96 (1.04%)"", ""  Dysphagia  1/96 (1.04%)"", ""  Mucositis oral  1/96 (1.04%)"", ""  Nausea  1/96 (1.04%)"", ""  Vomiting  2/96 (2.08%)"", ""  Death NOS  0/96 (0.00%)"", ""  Pain  1/96 (1.04%)"", ""  Catheter related infection  1/96 (1.04%)"", ""  Enterocolitis infectious  0/96 (0.00%)""]",Contradiction
"Throughout both NCT00767520 and NCT00455533 there was only one case of sudden and unexpected death, in cohort 1 of NCT00767520.","[""Adverse Events 1:"", ""  Total: 17/145 (11.72%)"", ""  ANAEMIA 0/145 (0.00%)"", ""  LEUKOPENIA 2/145 (1.38%)"", ""  NEUTROPENIA 1/145 (0.69%)"", ""  LEUKOCYTOSIS 1/145 (0.69%)"", ""  THROMBOCYTOPENIA 1/145 (0.69%)"", ""  FEBRILE NEUTROPENIA 1/145 (0.69%)"", ""  THROMBOTIC THROMBOCYTOPENIC PURPURA 0/145 (0.00%)"", ""  DISSEMINATED INTRAVASCULAR COAGULATION 0/145 (0.00%)"", ""  CARDIAC FAILURE 1/145 (0.69%)"", ""  ATRIAL FIBRILLATION 1/145 (0.69%)"", ""Adverse Events 2:"", ""  Total: 11/144 (7.64%)"", ""  ANAEMIA 1/144 (0.69%)"", ""  LEUKOPENIA 0/144 (0.00%)"", ""  NEUTROPENIA 0/144 (0.00%)"", ""  LEUKOCYTOSIS 0/144 (0.00%)"", ""  THROMBOCYTOPENIA 0/144 (0.00%)"", ""  FEBRILE NEUTROPENIA 1/144 (0.69%)"", ""  THROMBOTIC THROMBOCYTOPENIC PURPURA 1/144 (0.69%)"", ""  DISSEMINATED INTRAVASCULAR COAGULATION 1/144 (0.69%)"", ""  CARDIAC FAILURE 0/144 (0.00%)"", ""  ATRIAL FIBRILLATION 0/144 (0.00%)""]",Entailment
"Joe has had an alcohol addiction for 15 years, resulting in Cirrhosis therefore he is likely to be excluded from NCT01299038.","[""Inclusion Criteria:"", ""  Metastatic adenocarcinoma of the breast (Stage IV)"", ""  Actively receiving endocrine therapy for at least 6 weeks (with or without HER2 therapy)"", ""  Minimum age 18 years"", ""  ECOG Performance status of 0, 1 or 2"", ""  Normal organ and marrow function as defined in the protocol"", ""Exclusion Criteria:"", ""  Participants may not be receiving any other study agents"", ""  Actively receiving chemotherapy (exclusive of hormonal or HER2 therapy ) within last 5 weeks"", ""  Any statin therapy within the last 3 weeks"", ""  Asian decent (including Filipino, Chinese, Japanese, Korean, Vietnamese or Asian-Indian origin)"", ""  Concomitant use of the following drugs: cyclosporine, fibrates, niacin, gemfibrozil, ketaconazole, spironolactone, cimetidine, warfarin, erythromycin, or protease inhibitors"", ""  Conditions predisposing to renal failure secondary to rhabdomyolysis"", ""  Recent history of heavy alcohol use as judged by the treating physician"", ""  Known to be pregnant (testing not required) or nursing"", ""  History of rhabdomyolysis on statin therapy"", ""  Known history of Hepatitis C or active hepatitis B infection (baseline testing not required)"", ""  Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, hepatitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements""]",Entailment
Patients with HER2 positive breast or colon carcinoma are eligible for NCT00232479.,"[""Inclusion Criteria:"", ""  HER-2 overexpressing breast cancer""]",Contradiction
Cohort 1 of NCT01572727 recorded more white blood cell related adversse events than cohort 2.,"[""Adverse Events 1:"", ""  Total: 61/202 (30.20%)"", ""  FEBRILE NEUTROPENIA 1/202 (0.50%)"", ""  LEUKOPENIA 0/202 (0.00%)"", ""  NEUTROPENIA 2/202 (0.99%)"", ""  CARDIAC FAILURE CONGESTIVE 0/202 (0.00%)"", ""  CARDIO-RESPIRATORY ARREST 1/202 (0.50%)"", ""  PERICARDIAL EFFUSION 1/202 (0.50%)"", ""  CATARACT 1/202 (0.50%)"", ""  OPTIC NEUROPATHY 0/202 (0.00%)"", ""  ABDOMINAL PAIN 0/202 (0.00%)"", ""  CONSTIPATION 0/202 (0.00%)"", ""  DIARRHOEA 5/202 (2.48%)"", ""Adverse Events 2:"", ""  Total: 42/201 (20.90%)"", ""  FEBRILE NEUTROPENIA 0/201 (0.00%)"", ""  LEUKOPENIA 1/201 (0.50%)"", ""  NEUTROPENIA 0/201 (0.00%)"", ""  CARDIAC FAILURE CONGESTIVE 1/201 (0.50%)"", ""  CARDIO-RESPIRATORY ARREST 0/201 (0.00%)"", ""  PERICARDIAL EFFUSION 0/201 (0.00%)"", ""  CATARACT 1/201 (0.50%)"", ""  OPTIC NEUROPATHY 1/201 (0.50%)"", ""  ABDOMINAL PAIN 1/201 (0.50%)"", ""  CONSTIPATION 1/201 (0.50%)"", ""  DIARRHOEA 3/201 (1.49%)""]",Entailment
Patients with ERBB2 positive tumors are eligible for NCT00741260.,"[""INCLUSION CRITERIA"", ""  erbB-2 gene amplified tumor (FISH or CISH) or erbB-2 overexpression (IHC 3+, or IHC2+ with FISH or CISH confirmation), based on local testing, or based on centralized FISH testing prior to day 1.""]",Entailment
"NCT02445586 reported more cases of Haematemesis, but NCT00789581 had more cases of Sinus tachycardia.","[""Adverse Events 1:"", ""  Total: 58/305 (19.02%)"", ""  FEBRILE NEUTROPENIA * 12/305 (3.93%)"", ""  NEUTROPENIA * 4/305 (1.31%)"", ""  ANAEMIA * 2/305 (0.66%)"", ""  LEUKOPENIA * 1/305 (0.33%)"", ""  PANCYTOPENIA * 1/305 (0.33%)"", ""  THROMBOCYTOPENIA * 1/305 (0.33%)"", ""  DISSEMINATED INTRAVASCULAR COAGULATION * 0/305 (0.00%)"", ""  ATRIAL FIBRILLATION * 1/305 (0.33%)"", ""  DIASTOLIC DYSFUNCTION * 1/305 (0.33%)"", ""  PERICARDIAL EFFUSION * 1/305 (0.33%)"", ""Adverse Events 2:"", ""  Total: 50/304 (16.45%)"", ""  FEBRILE NEUTROPENIA * 12/304 (3.95%)"", ""  NEUTROPENIA * 1/304 (0.33%)"", ""  ANAEMIA * 0/304 (0.00%)"", ""  LEUKOPENIA * 0/304 (0.00%)"", ""  PANCYTOPENIA * 0/304 (0.00%)"", ""  THROMBOCYTOPENIA * 0/304 (0.00%)"", ""  DISSEMINATED INTRAVASCULAR COAGULATION * 1/304 (0.33%)"", ""  ATRIAL FIBRILLATION * 1/304 (0.33%)"", ""  DIASTOLIC DYSFUNCTION * 0/304 (0.00%)"", ""  PERICARDIAL EFFUSION * 0/304 (0.00%)""]",Contradiction
"The most common adverse event in NCT01256567 was Febrile neutropenia (42.86%), whereas in NCT01926886 it was a decrease in Ejection fraction (4.95%).","[""Adverse Events 1:"", ""  Total: 7/7 (100.00%)"", ""  Febrile neutropenia 3/7 (42.86%)"", ""  Cardiac failure 1/7 (14.29%)"", ""  Neutrophil count decreased 1/7 (14.29%)"", ""  Muscular weakness 1/7 (14.29%)"", ""  Epistaxis 1/7 (14.29%)"", ""  Interstitial lung disease 1/7 (14.29%)"", ""  Pleural effusion 2/7 (28.57%)""]",Entailment
1 patient in NCT01276041 died in an event not associated with a specifc CTCAE term.,"[""Adverse Events 1:"", ""  Total: 18/70 (25.71%)"", ""  Cardiac arrest  1/70 (1.43%)"", ""  Pericardial effusion  1/70 (1.43%)"", ""  Ear pain  1/70 (1.43%)"", ""  Blurred vision  1/70 (1.43%)"", ""  Eye disorders - Other, specify  2/70 (2.86%)"", ""  Abdominal Pain  5/70 (7.14%)"", ""  Colitis  1/70 (1.43%)"", ""  Diarrhea  2/70 (2.86%)"", ""  Nausea  2/70 (2.86%)"", ""  Death NOS  1/70 (1.43%)"", ""  Edema limbs  1/70 (1.43%)"", ""  Fatigue  3/70 (4.29%)""]",Entailment
"In order to be eligible for both NCT03045653 and NCT00499083, patients must be female, over the age of 18, ECOG <2 and have Histologically confirmed HER2 + breast cancer.","[""  HER2/neu-negative tumor by IHC"", ""  Female"", ""  ECOG performance status 0-1""]",Contradiction
"Unlike NCT00479674, NCT01252290 does not record any instances of Anemia, Dyspepsia, Nausea or depression.","[""Adverse Events 1:"", ""  Total: 2/35 (5.71%)"", ""  Gastroesophageal reflux disease * 1/35 (2.86%)"", ""  Ductal carcinoma in situ * 1/35 (2.86%)""]",Contradiction
Less than 5 patients in NCT01095003 experienced Earache.,"[""Adverse Events 1:"", ""  Total: 107/383 (27.94%)"", ""  Anaemia 4/383 (1.04%)"", ""  Febrile neutropenia 7/383 (1.83%)"", ""  Haemoytique anaemia 0/383 (0.00%)"", ""  Leukopenia 1/383 (0.26%)"", ""  Neutropenia 6/383 (1.57%)"", ""  Thrombocytopenia 2/383 (0.52%)"", ""  Anginal pectoris 1/383 (0.26%)"", ""  Cardiomyopathy 0/383 (0.00%)"", ""  Ear pain 0/383 (0.00%)"", ""  Abdominal distension 1/383 (0.26%)"", ""  Abdominal pain 6/383 (1.57%)"", ""Adverse Events 2:"", ""  Total: 85/383 (22.19%)"", ""  Anaemia 3/383 (0.78%)"", ""  Febrile neutropenia 2/383 (0.52%)"", ""  Haemoytique anaemia 0/383 (0.00%)"", ""  Leukopenia 0/383 (0.00%)"", ""  Neutropenia 1/383 (0.26%)"", ""  Thrombocytopenia 1/383 (0.26%)"", ""  Anginal pectoris 0/383 (0.00%)"", ""  Cardiomyopathy 1/383 (0.26%)"", ""  Ear pain 1/383 (0.26%)"", ""  Abdominal distension 0/383 (0.00%)"", ""  Abdominal pain 3/383 (0.78%)""]",Entailment
1 patient in NCT01610284 had an abrupt loss of heart function.,"[""Adverse Events 1:"", ""  Total: 146/573 (25.48%)"", ""  Anaemia 4/573 (0.70%)"", ""  Disseminated intravascular coagulation 0/573 (0.00%)"", ""  Neutropenia 1/573 (0.17%)"", ""  Thrombocytopenia 0/573 (0.00%)"", ""  Acute coronary syndrome 1/573 (0.17%)"", ""  Angina pectoris 1/573 (0.17%)"", ""  Atrial fibrillation 2/573 (0.35%)"", ""  Atrial flutter 0/573 (0.00%)"", ""  Cardiac arrest 1/573 (0.17%)"", ""  Cardiac failure 0/573 (0.00%)"", ""Adverse Events 2:"", ""  Total: 101/570 (17.72%)"", ""  Anaemia 3/570 (0.53%)"", ""  Disseminated intravascular coagulation 1/570 (0.18%)"", ""  Neutropenia 1/570 (0.18%)"", ""  Thrombocytopenia 1/570 (0.18%)"", ""  Acute coronary syndrome 0/570 (0.00%)"", ""  Angina pectoris 1/570 (0.18%)"", ""  Atrial fibrillation 0/570 (0.00%)"", ""  Atrial flutter 1/570 (0.18%)"", ""  Cardiac arrest 0/570 (0.00%)"", ""  Cardiac failure 1/570 (0.18%)""]",Entailment
NCT02366130 and NCT01262027 have entirely different adverse event profiles.,"[""Adverse Events 1:"", ""  Total: 28/36 (77.78%)"", ""  Lymphocytopenia 210/36 (27.78%)"", ""  Neutropenia 29/36 (25.00%)"", ""  Anemia 26/36 (16.67%)"", ""  Thrombocytopenia 24/36 (11.11%)"", ""  Hyperglycemia 27/36 (19.44%)"", ""  Nausea 213/36 (36.11%)"", ""  Diarrhea 211/36 (30.56%)"", ""  Fatigue 215/36 (41.67%)"", ""  Flu-like symptoms 26/36 (16.67%)"", ""  Hot Flashes 25/36 (13.89%)"", ""  AST/ALT elevation 211/36 (30.56%)"", ""  Arthralgia 24/36 (11.11%)""]",Entailment
Male patients with Systemic lupus erythematosus are excluded from NCT00847171 but may still be eligible for NCT01764022.,"[""  No prior or currently active autoimmune disease* requiring management with systemic immunosuppression, including any of the following:"", ""  Systemic lupus erythematosus""]",Contradiction
Patients must be over the age of 18 and have a life expectancy over 6 months to participate in NCT00193050 or NCT00232479.,"[""Inclusion Criteria:"", ""  Female Patients >18 years of age"", ""Exclusion Criteria:"", ""  Life expectancy of < than 6 months""]",Contradiction
There were 0 patients with Dysphagia or Fever in NCT01596751 and NCT00193050 cohorts.,"[""  Dysphagia 0/5 (0.00%)"", ""  Fever 0/5 (0.00%)""]",Entailment
Patients with undetermined estrogen receptor status can be accepted by both NCT02244580 and NCT01901146.,"[""Inclusion Criteria:"", ""  Estrogen receptor (ER), PgR and HER2 expression have been determined""]",Contradiction
"Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or sensory neuropathy, are eligible for NCT01028352.","[""Inclusion Criteria:"", ""  AI-associated musculoskeletal symptoms, defined as:"", ""  Grade 1 or higher musculoskeletal pain that developed or worsened (6 or 7 on CGICS) during AI therapy or"", ""  Grade 1 or higher sensory neuropathy that developed or worsened (6 or 7 on CGICS) during AI therapy;""]",Entailment
None of the patients in cohort 1 of NCT00266799 had ACUTE VESTIBULAR or acute coronary syndrome.,"[""Adverse Events 1:"", ""  Total: 30/98 (30.61%)"", ""  NEUTROPENIA 1/98 (1.02%)"", ""  ATRIAL FIBRILLATION 1/98 (1.02%)"", ""  CARDIAC FAILURE 1/98 (1.02%)"", ""  TACHYCARDIA 0/98 (0.00%)"", ""  ACUTE VESTIBULAR SYNDROME 1/98 (1.02%)"", ""  VERTIGO 0/98 (0.00%)"", ""  ABDOMINAL PAIN 0/98 (0.00%)"", ""  COLITIS 0/98 (0.00%)"", ""  DIARRHOEA 2/98 (2.04%)"", ""  FEMORAL HERNIA 0/98 (0.00%)"", ""  HAEMATEMESIS 0/98 (0.00%)"", ""  ILEUS 0/98 (0.00%)"", ""  NAUSEA 0/98 (0.00%)""]",Contradiction
"Cohort 1 and 2 of NCT00879086 had the same number of patients with anaemia and Neutropenia, but Cohort 1 had 1 more case of Leukopenia than cohort 2.","[""Adverse Events 1:"", ""  Anaemia 1/51 (1.96%)"", ""  Leukopenia 1/51 (1.96%)"", ""  Neutropenia 1/51 (1.96%)"", ""Adverse Events 2:"", ""  Anaemia 1/50 (2.00%)"", ""  Leukopenia 0/50 (0.00%)"", ""  Neutropenia 1/50 (2.00%)""]",Entailment
In total there were more adverse events in cohort 1 of NCT00426556 than in cohort 2 of NCT00559845.,"[""Adverse Events 1:"", ""  Total: 8/54 (14.81%)"", ""  Anaemia 1/54 (1.85%)"", ""  Febrile Neutropenia 1/54 (1.85%)"", ""  Retinopathy Hypertensive 1/54 (1.85%)"", ""  Febrile Infection 1/54 (1.85%)"", ""  Postoperative Wound Complication 1/54 (1.85%)"", ""  Cardiac Imaging Procedure Abnormal 1/54 (1.85%)"", ""  Malignant Melanoma In Situ 1/54 (1.85%)"", ""  Suicide Attempt 1/54 (1.85%)"", ""  Dyspnoea 1/54 (1.85%)""]",Contradiction
At most 3 patients in NCT00022516 suffered from Neutropenia.,"[""Adverse Events 1:"", ""  Total: 0/0"", ""  Leukopenia 0/0"", ""  Neutropenia 0/0"", ""  Ocular-other 0/0"", ""  Elevated SGPT 0/0"", ""  Arthralgia 0/0"", ""  CNS hemorrhage 0/0"", ""  Neurologic-other 0/0"", ""  Radiation dermatitis 0/0"", ""Adverse Events 2:"", ""  Total: 11/473 (2.33%)"", ""  Leukopenia 2/473 (0.42%)"", ""  Neutropenia 5/473 (1.06%)"", ""  Ocular-other 1/473 (0.21%)"", ""  Elevated SGPT 1/473 (0.21%)"", ""  Arthralgia 1/473 (0.21%)"", ""  CNS hemorrhage 1/473 (0.21%)"", ""  Neurologic-other 1/473 (0.21%)"", ""  Radiation dermatitis 1/473 (0.21%)""]",Contradiction
"Completely disabled patients, totally confined to bed or chair and unable to carry on any selfcare are eligible for NCT00568022 but excluded from NCT01120184.","[""Inclusion Criteria:"", ""  Women  20 years"", ""  Histologically or cytologically confirmed diagnosis of adenocarcinoma originating in the breast"", ""Exclusion Criteria:"", ""  Number of prior chemotherapy lines of treatment in the metastatic setting 3""]",Entailment
60 patients in NCT00270894 were able to Complete at least 85% of the Planned Dose on Schedule.,"[""Outcome Measurement: "", ""  Percentage of Subjects Able to Complete > 85% of the Planned Dose on Schedule"", ""  Feasibility will be determined by evaluating the percentage of subjects able to complete the neoadjuvant portion of the study on time with > 85% of the protocol-specified dose."", ""  Time frame: From the start of treatment through the neoadjuvant treatment period (approximately 20 weeks)"", ""Results 1: "", ""  Arm/Group Title: Neoadjuvant Therapy"", ""  Arm/Group Description: Neoadjuvant therapy will consist of epirubicin (100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m^2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments."", ""  Overall Number of Participants Analyzed: 30"", ""  Measure Type: Number"", ""  Unit of Measure: percentage of participants  60""]",Contradiction
"Women with chronic obstructive pulmonary disease that do not require systemic corticosteroids, are eligible for NCT00399529.","[""  No prior or currently active autoimmune disease requiring management with systemic immunosuppression. This includes inflammatory bowel disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia or immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, sarcoidosis, or other rheumatologic disease. Asthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids is acceptable.""]",Entailment
Patients with non-measurable diseases are only eligible for phase I of NCT01105312.,"[""  Measurable or non-measurable disease for phase I study (The Phase I portion of this study closed and the Phase II portion of the study opened as per NCCTG Addendum 6, effective January 23, 2012.)"", ""  Measurable disease only for phase II study""]",Entailment
Only men can be eligible for NCT00605267.,"[""Inclusion Criteria:"", ""  Premenopausal, estrogen receptor positive women, aged 20 years and over, with operable and measurable breast cancer who have provided written informed consent"", ""Exclusion Criteria:"", ""  Medical history of chemotherapy or endocrine therapy for breast cancer, or with treatment history of radiotherapy. Unwillingness to stop taking any drug known to affect sex hormone status (including hormone replacement therapy (HRT).""]",Contradiction
The maximum number of occurences for an adverse event in NCT02502864 was 3.,"[""Adverse Events 1:"", ""  Total: 3/9 (33.33%)"", ""  Fatigue * 1/9 (11.11%)"", ""  Non-cardiac chest pain * 1/9 (11.11%)"", ""  Sepsis * 1/9 (11.11%)"", ""  Urinary tract infection * 1/9 (11.11%)"", ""  Syncope * 1/9 (11.11%)"", ""  Anxiety * 1/9 (11.11%)"", ""  Thromboembolic event * 1/9 (11.11%)""]",Contradiction
1 patient in NCT00679211 was diangosed with Influenza.,"[""Adverse Events 1:"", ""  Influenza like illness 1/110 (0.91%)""]",Contradiction
"Patients with permanent sensory loss, interfering with daily activities are excluded from NCT00129389, but may still be eligible for NCT00304096.","[""Exclusion Criteria:"", ""  Pre-existing grade >=2 motor or sensorial neurotoxicity by the National Cancer Institute Common Toxicity Criteria (NCICTC) v-2.0.""]",Entailment
There were no patients in either cohort of NCT00022672 with a PFS exceeding one year.,"[""Outcome Measurement: "", ""  Progression Free Survival (PFS)"", ""  PFS was assessed by the investigator based on World Health Organization (WHO) criteria using radiographic tumor evaluations. Disease progression was defined as the appearance of any new lesion not previously identified or an estimated increase of 25% or more in existent bidimensionally or unidimensionally measurable lesions or progression of an existing non-measurable lesion. For bidimensionally measurable malignant lesions with an area of at least 2.0 centimeters squared (cm^2) an increase of 1.0 cm^2 was required and for unidimensionally measurable lesions of 1.0 cm or less an increase of 0.5 cm was required. PFS was defined as the number of days between date of randomization and date of documented disease progression or date of death. Kaplan Meier estimates of PFS are presented."", ""  Time frame: 24 Months, End of Study (Up to 5 years)"", ""Results 1: "", ""  Arm/Group Title: Trastuzumab + Anastrozole"", ""  Arm/Group Description: Trastuzumab 4 mg/kg loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole every day for 24 Months in the Main phase and in the Extension Phase."", ""  Overall Number of Participants Analyzed: 103"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: Months  24 Months: 4.8        (3.7 to 7)"", ""  End of Study: 5.8        (4.6 to 8.3)"", ""Results 2: "", ""  Arm/Group Title: Anastrozole"", ""  Arm/Group Description: 1 mg oral dose of anastrozole every day for 24 Months in the Main phase. In the Extension Phase participants could cross-over to also receive trastuzumab 4 mg/kg initial loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes."", ""  Overall Number of Participants Analyzed: 104"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: Months  24 Months: 2.4        (2 to 4.6)"", ""  End of Study: 2.9        (2.1 to 4.5)""]",Entailment
There were 4 different Gastrointestinal adverse events recorded in cohort 1 of NCT00591851.,"[""Adverse Events 1:"", ""  Abdominal Pain 2/70 (2.86%)"", ""  Diarrhea 21/70 (1.43%)"", ""  Lower gastrointestinal hemorrhage 21/70 (1.43%)"", ""  Nausea 21/70 (1.43%)""]",Entailment
Cohort 1 of NCT00490646 had 25% more patients experiencing Cholecystitis than cohort 2.,"[""Adverse Events 1:"", ""  Total: 13/24 (54.17%)"", ""  FEBRILE NEUTROPENIA 5/24 (20.83%)"", ""  HAEMATOTOXICITY 0/24 (0.00%)"", ""  NEUTROPENIA 3/24 (12.50%)"", ""  LYMPHADENOPATHY 0/24 (0.00%)"", ""  PERICARDIAL EFFUSION 1/24 (4.17%)"", ""  ATRIAL FIBRILLATION 1/24 (4.17%)"", ""  APLASIA 0/24 (0.00%)"", ""  NAUSEA 0/24 (0.00%)"", ""  PYREXIA 1/24 (4.17%)"", ""  EXTRAVASATION 0/24 (0.00%)"", ""  CHOLECYSTITIS 1/24 (4.17%)"", ""  PATHOLOGICAL FRACTURE 1/24 (4.17%)"", ""Adverse Events 2:"", ""  Total: 6/24 (25.00%)"", ""  FEBRILE NEUTROPENIA 0/24 (0.00%)"", ""  HAEMATOTOXICITY 1/24 (4.17%)"", ""  NEUTROPENIA 0/24 (0.00%)"", ""  LYMPHADENOPATHY 1/24 (4.17%)"", ""  PERICARDIAL EFFUSION 0/24 (0.00%)"", ""  ATRIAL FIBRILLATION 0/24 (0.00%)"", ""  APLASIA 1/24 (4.17%)"", ""  NAUSEA 1/24 (4.17%)"", ""  PYREXIA 0/24 (0.00%)"", ""  EXTRAVASATION 1/24 (4.17%)"", ""  CHOLECYSTITIS 0/24 (0.00%)"", ""  PATHOLOGICAL FRACTURE 0/24 (0.00%)""]",Contradiction
Cohort 1 of NCT00887575 recorded more cases of diarrhea and dyspepsia than cohort 1 of NCT02491892.,"[""Adverse Events 1:"", ""  Diarrhoea * 0/41 (0.00%)"", ""  Dysphagia * 0/41 (0.00%)""]",Entailment
There were no cases of Intracranial hemorrhage in NCT02370238.,"[""Adverse Events 1:"", ""  Total: 13/61 (21.31%)"", ""  Anaemia 1/61 (1.64%)"", ""  Febrile neutropenia 1/61 (1.64%)"", ""  Cardiac failure congestive 0/61 (0.00%)"", ""  Pericardial effusion 0/61 (0.00%)"", ""  Constipation 1/61 (1.64%)"", ""  Intestinal perforation 1/61 (1.64%)"", ""  Stomatitis 0/61 (0.00%)"", ""  Non-cardiac chest pain 2/61 (3.28%)"", ""  Condition aggravated 1/61 (1.64%)"", ""  General physical health deterioration 1/61 (1.64%)"", ""Adverse Events 2:"", ""  Total: 12/60 (20.00%)"", ""  Anaemia 1/60 (1.67%)"", ""  Febrile neutropenia 0/60 (0.00%)"", ""  Cardiac failure congestive 1/60 (1.67%)"", ""  Pericardial effusion 1/60 (1.67%)"", ""  Constipation 0/60 (0.00%)"", ""  Intestinal perforation 0/60 (0.00%)"", ""  Stomatitis 1/60 (1.67%)"", ""  Non-cardiac chest pain 0/60 (0.00%)"", ""  Condition aggravated 0/60 (0.00%)"", ""  General physical health deterioration 1/60 (1.67%)""]",Entailment
NCT00656669 recorded 23 adverse events.,"[""Adverse Events 1:"", ""  Total: 0/23 (0.00%)""]",Contradiction
"NCT00899574 uses different inclusion criteria for its cohorts, NCT01007942 only uses one set on inclusion criteria for all cohorts.","[""Inclusion Criteria:"", ""  (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator."", ""  (Cohort 2) Any concurrent systemic therapy is allowed""]",Entailment
There was no adverse event in cohort 2 of NCT00320710 which occurred in more than 5% of patients.,"[""Adverse Events 2:"", ""  Anaemia 3/202 (1.49%)"", ""  Febrile neutropenia 2/202 (0.99%)"", ""  Leukocytosis 0/202 (0.00%)"", ""  Leukopenia 0/202 (0.00%)"", ""  Neutropenia 0/202 (0.00%)"", ""  Pancytopenia 1/202 (0.50%)"", ""  Atrial fibrillation 1/202 (0.50%)"", ""  Cardiac failure congestive 1/202 (0.50%)"", ""  Palpitations 1/202 (0.50%)"", ""  Pericardial effusion 1/202 (0.50%)"", ""  Supraventricular tachycardia 1/202 (0.50%)""]",Entailment
At least 1 participant in NCT01300351 showed signs of poor liver function.,"[""Adverse Events 1:"", ""  Hepatic function abnormal * 1/109 (0.92%)""]",Entailment
A patient with minimal symptoms but a severe obstruction of the left main coronary artery would be unable to participate in NCT00054275.,"[""  No New York Heart Association class III or IV heart disease"", ""  No unstable angina pectoris""]",Contradiction
NCT01048099 recorded 2 more total adverse events than NCT02502864,"[""Adverse Events 1:"", ""  Total: 5/14 (35.71%)""]",Contradiction
Less than 1/4 patients in NCT03066947 experienced adverse events.,"[""Adverse Events 1:"", ""  Total: 8/24 (33.33%)""]",Contradiction
"NCT00899574 and NCT01007942 use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other.","[""Inclusion Criteria:"", ""  (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator."", ""  (Cohort 2) Any concurrent systemic therapy is allowed""]",Contradiction
Respiratory illnesses were observed in most of the patients in NCT02536339 and NCT00371345.,"[""Adverse Events 1:"", ""  Total: 7/39 (17.95%)"", ""  Gastroenteritis viral 1/39 (2.56%)"", ""  Parainfluenzae virus infection 1/39 (2.56%)"", ""  Seizure 4/39 (10.26%)"", ""  Headache 1/39 (2.56%)"", ""  Hydrocephalus 1/39 (2.56%)"", ""  Hypertension 1/39 (2.56%)""]",Contradiction
There were 0 observed cases of Tibia or Fibula fractures in NCT01752907.,"[""Adverse Events 1:"", ""  Total: 16/149 (10.74%)"", ""  Anaemia 0/149 (0.00%)"", ""  Febrile neutropenia 7/149 (4.70%)"", ""  Neutropenia 1/149 (0.67%)"", ""  Pancytopenia 1/149 (0.67%)"", ""  Atrial fibrillation 2/149 (1.34%)"", ""  Cardiac failure congestive 0/149 (0.00%)"", ""  Abdominal pain 0/149 (0.00%)"", ""  Diarrhoea 2/149 (1.34%)"", ""  Dyspepsia 0/149 (0.00%)"", ""  Gastritis haemorrhagic 0/149 (0.00%)"", ""  Nausea 2/149 (1.34%)"", ""Adverse Events 2:"", ""  Total: 20/151 (13.25%)"", ""  Anaemia 1/151 (0.66%)"", ""  Febrile neutropenia 4/151 (2.65%)"", ""  Neutropenia 2/151 (1.32%)"", ""  Pancytopenia 0/151 (0.00%)"", ""  Atrial fibrillation 0/151 (0.00%)"", ""  Cardiac failure congestive 1/151 (0.66%)"", ""  Abdominal pain 1/151 (0.66%)"", ""  Diarrhoea 3/151 (1.99%)"", ""  Dyspepsia 1/151 (0.66%)"", ""  Gastritis haemorrhagic 1/151 (0.66%)"", ""  Nausea 1/151 (0.66%)""]",Entailment
"NCT01961544 reported a combined total of 3 cases of Pericardial effusion, Asthenia and Gastritis in cohort 1.","[""Adverse Events 1:"", ""  Pericardial effusion * 2/101 (1.98%)"", ""  Gastritis * 1/101 (0.99%)"", ""  Asthenia * 1/101 (0.99%)""]",Contradiction
"Sharone had a hip replacement 2 months prior, she is not elgible for NCT03045653.","[""Exclusion Criteria:"", ""  Major surgery (excluding placement of vascular access) within 4 weeks before study treatment Evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and HIV With the exception of alopecia, any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment Elevated ALP in absence of bone metastasis Evidence of dementia, altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent Participation in another study with investigational product during last 30 days Inability or unwillingness to comply with study procedures, including inability to take regular oral medication""]",Contradiction
Patients with aspartate aminotransferase more than 2 times the upper limit of normal are excluded from both NCT00834678 but eligible for NCT01593020.,"[""Exclusion Criteria:"", ""  AST or ALT > 2.5 times the upper limit of normal (ULN)""]",Contradiction
"Patients must have BUN < 20 mg/dL,  Platelet count: <90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 to be eligible for either NCT00438100 or NCT00662025.","[""Inclusion Criteria:"", ""  Biopsy-diagnosed breast cancer with metastasis in multiple organs"", ""  Performance Status (World Health Organization :WHO) 0-2"", ""  Functions below are maintained in major organs:"", ""  Leukocyte count: 4,000/mm3 to 12,000/mm3"", ""  Neutrophil count: >2,000/mm3 or more"", ""  Platelet count: <100,000/mm3 or more"", ""  Hemoglobin: >9.5 g/dL"", ""  Total bilirubin: >1.5 mg/dL"", ""  AST(GOT): within twice a normal upper value in an institution"", ""  AST(GPT): within twice a normal upper value in an institution"", ""  BUN: < 25 mg/dL"", ""  Creatinine: within a normal upper value in the institution"", ""  24 hours creatinine clearance: >50 mL/min (using the Cockcroft-Gault formula)"", ""  Women's Ccr = Body weight x (140-Age)/(72 x Serum creatinine) x 0.85""]",Contradiction
"Patients with cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for NCT01506609.","[""Inclusion Criteria:"", ""  Histologically or cytologically confirmed breast cancer that is either locally recurrent or metastatic."", ""  Locally recurrent disease must not be amenable to surgical resection or radiation with curative intent.""]",Entailment
Patients must have a triple negative infiltrating breast carcinoma to participate in NCT00127933 or NCT00201760.,"[""Eligibility Criteria:"", ""  Must have invasive metastatic breast cancer"", ""  Tumor must be Her 2/neu 3+ by IHC (must be confirmed by Ohio State University pathology)or positive FISH""]",Contradiction
There are a total of 14 cases of neutropenia related adverse events in NCT00274456 across both cohorts.,"[""Adverse Events 1:"", ""  Total: 14/76 (18.42%)"", ""  Neutropenia 10/76 (13.16%)"", ""  Febrile neutropenia 1/76 (1.32%)"", ""  Anaemia 0/76 (0.00%)"", ""  Thrombocytopenia 0/76 (0.00%)"", ""  Cardiopulmonary failure 0/76 (0.00%)"", ""  Optic ischaemic neuropathy 0/76 (0.00%)"", ""  Bowel peristalsis increased 1/76 (1.32%)"", ""  Colitis 0/76 (0.00%)"", ""  Diarrhoea 0/76 (0.00%)"", ""  Gastritis 0/76 (0.00%)"", ""  Nausea 0/76 (0.00%)"", ""Adverse Events 2:"", ""  Total: 12/76 (15.79%)"", ""  Neutropenia 2/76 (2.63%)"", ""  Febrile neutropenia 1/76 (1.32%)"", ""  Anaemia 0/76 (0.00%)"", ""  Thrombocytopenia 0/76 (0.00%)"", ""  Cardiopulmonary failure 1/76 (1.32%)"", ""  Optic ischaemic neuropathy 1/76 (1.32%)"", ""  Bowel peristalsis increased 0/76 (0.00%)"", ""  Colitis 1/76 (1.32%)"", ""  Diarrhoea 0/76 (0.00%)"", ""  Gastritis 0/76 (0.00%)"", ""  Nausea 1/76 (1.32%)""]",Entailment
"NCT00392392 records two different types of pain in its adverse events, in the cranial and foot area, NCT00503906 does not record any types of pain in its participants. ","[""Adverse Events 1:"", ""  Pain - Abdomen 1/29 (3.45%)"", ""  Pain - Chest 1/29 (3.45%)""]",Contradiction
"Patients with Class III obesity cannot be included in NCT02650193, but can be entered into NCT00656669, as long as they do not have uncontrolled Hypertension.","[""Inclusion Criteria:"", ""  Body mass index (BMI) of 19 to 40 kg/m^2 , inclusive""]",Entailment
"There was one case of hemorrhaging in NCT02139358, and no recorded cases in NCT02574455.","[""Adverse Events 1:"", ""  Total: 7/15 (46.67%)"", ""  Cardiac arrest * 1/15 (6.67%)"", ""  Chest pain - cardiac * 1/15 (6.67%)"", ""  Diarrhea * 1/15 (6.67%)"", ""  Duodenal hemorrhage * 1/15 (6.67%)"", ""  Fatigue * 1/15 (6.67%)"", ""  Fever * 1/15 (6.67%)"", ""  Sudden death NOS * 1/15 (6.67%)"", ""  Sepsis * 1/15 (6.67%)"", ""  Skin infection * 1/15 (6.67%)"", ""  Neutrophil count decreased * 1/15 (6.67%)"", ""  Platelet count decreased * 1/15 (6.67%)""]",Entailment
NCT01840163 and NCT02005549 do not exclude patients with concurrent systemic antitumor therapy.,"[""Inclusion Criteria:"", ""  Stage 1-2 invasive breast cancer diagnosis,"", ""  DCIS"", ""  Ability to read English"", ""Exclusion Criteria:"", ""Male""]",Contradiction
Patients with Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for NCT00633750.,"[""Inclusion Criteria:"", ""  Clinical stage I or II (T1 or T2, N0 or N1) invasive mammary carcinoma"", ""Exclusion Criteria:"", ""  Fixed axillary lymph node metastases (N2)""]",Contradiction
"1 patient in NCT00679211 presented a fever, in addition to either a cough or a sore throat.","[""Adverse Events 1:"", ""  Influenza like illness 1/110 (0.91%)""]",Entailment
Patients do not need to have a Her2neu positive tumours or a measurable indicator lesion to be included in NCT00191854,"[""Inclusion Criteria:"", ""  Female patients with histological or cytological proven diagnosis of breast cancer"", ""  Stage IV disease"", ""  Performance Status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Scale"", ""  Patients had to have previously received anthracycline based regimens as a adjuvant therapy or neo-adjuvant chemotherapy and then progressed and developed metastatic disease"", ""  Adequate organ function"", ""Exclusion Criteria:"", ""  Prior chemotherapy for metastatic disease"", ""  Previous radiation therapy is allowed but must not have included whole pelvis radiation"", ""  Known or suspected brain metastasis. Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator"", ""  Concurrent administration of any other tumor therapy, including cytotoxic chemotherapy, hormonal therapy and immunotherapy (including trastuzumab (Herceptin))"", ""  Peripheral neuropathy of Common Toxicity Criteria (CTC) Grade greater than 1. History of significant neurological or mental disorder, including seizures or dementia""]",Entailment
"Fiona's step sister, who is 34 years old was diagnosed with a ductal carcinoma, therefore fiona may be eligible for NCT01252277.","[""Inclusion Criteria"", ""  A first degree relative with breast cancer under the age of 60 or multiple second degree relatives with breast cancer.""]",Contradiction
"To be eligible for NCT01027416, patients must have an invasive carcinoma confirmed by core biopsy, and a -ive human chorionic gonadotropin urine test.","[""Inclusion Criteria:"", ""  Core biopsy should definitively demonstrate invasive carcinoma."", ""  Negative serum or urine beta-hCG pregnancy test at screening for patients of child-bearing potential (this is routinely done if the patient is premenopausal and having surgery)""]",Contradiction
Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for NCT01527487.,"[""Exclusion Criteria:"", ""  Chronic use of drugs that cause QTc prolongation. Patients must discontinue use of these drugs 7 days prior to the start of study treatment.""]",Entailment
Patients with Breast cancers that have estrogen receptors are excluded from NCT00635050.,"[""Inclusion Criteria:"", ""  Patients with node-negative, ER or PR-positive tumors 4 cm in size whose tumors are low risk (defined as a score of 0-17) on an Oncotype DX profile are not eligible.""]",Entailment
Patients with Grade I peripheral neuropathy or above are eliminated from participation in NCT00932373.,"[""Exclusion Criteria:"", ""  Grade  2 peripheral neuropathy""]",Contradiction
No cases of Anaphylaxis occurred in either NCT01234337 or NCT00217672.,"[""Adverse Events 1:"", ""  Total: 80/260 (30.77%)"", ""  Anaemia * 2/260 (0.77%)"", ""  Febrile neutropenia * 0/260 (0.00%)"", ""  Neutropenia * 2/260 (0.77%)"", ""  Thrombocytopenia * 0/260 (0.00%)"", ""  Bundle branch block right * 0/260 (0.00%)"", ""  Pericardial effusion * 0/260 (0.00%)"", ""  Cardiopulmonary failure * 0/260 (0.00%)"", ""  Aplasia * 0/260 (0.00%)"", ""  Eye symptom * 1/260 (0.38%)"", ""  Abdominal discomfort * 0/260 (0.00%)"", ""Adverse Events 2:"", ""  Total: 71/267 (26.59%)"", ""  Anaemia * 2/267 (0.75%)"", ""  Febrile neutropenia * 1/267 (0.37%)"", ""  Neutropenia * 0/267 (0.00%)"", ""  Thrombocytopenia * 1/267 (0.37%)"", ""  Bundle branch block right * 1/267 (0.37%)"", ""  Pericardial effusion * 5/267 (1.87%)"", ""  Cardiopulmonary failure * 1/267 (0.37%)"", ""  Aplasia * 1/267 (0.37%)"", ""  Eye symptom * 0/267 (0.00%)"", ""  Abdominal discomfort * 1/267 (0.37%)""]",Entailment
NCT00399529 and NCT00754325 both accept patients with HER-2/neu-overexpressing adenocarcinoma of the breast.,"[""Inclusion Criteria:"", ""  Histologically confirmed hormone receptor positive (HR+) [(estrogen receptor (ER+) and/or progesterone receptors(PgR+)] breast cancer according to immunohistochemistry (IHC)""]",Entailment
There were 4 cases of Febrile neutropenia and heart failure in cohort 1 of NCT01491737.,"[""Adverse Events 1:"", ""  Febrile neutropenia 4/127 (3.15%)"", ""  Cardiac failure 0/127 (0.00%)""]",Contradiction
At least 1 patient in NCT00022516 suffered from a radiotherapy induced adverse event.,"[""Adverse Events 1:"", ""  Total: 0/0"", ""  Leukopenia 0/0"", ""  Neutropenia 0/0"", ""  Ocular-other 0/0"", ""  Elevated SGPT 0/0"", ""  Arthralgia 0/0"", ""  CNS hemorrhage 0/0"", ""  Neurologic-other 0/0"", ""  Radiation dermatitis 0/0"", ""Adverse Events 2:"", ""  Total: 11/473 (2.33%)"", ""  Leukopenia 2/473 (0.42%)"", ""  Neutropenia 5/473 (1.06%)"", ""  Ocular-other 1/473 (0.21%)"", ""  Elevated SGPT 1/473 (0.21%)"", ""  Arthralgia 1/473 (0.21%)"", ""  CNS hemorrhage 1/473 (0.21%)"", ""  Neurologic-other 1/473 (0.21%)"", ""  Radiation dermatitis 1/473 (0.21%)""]",Entailment
Every patient in the Palbociclib+Letrozole Australia Cohort of NCT02679755 experienced Treatment-Emergent Adverse Events.,"[""Outcome Measurement: "", ""  Number of Participants With Treatment-Emergent Adverse Events (All Causalities)"", ""  An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as treatment emergent adverse events (TEAEs). AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly."", ""  Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months"", ""Results 2: "", ""  Arm/Group Title: Palbociclib+Letrozole Australia Cohort"", ""  Arm/Group Description: Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment for each 28-day cycle. Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information"", ""  Overall Number of Participants Analyzed: 152"", ""  Measure Type: Count of Participants"", ""  Unit of Measure: Participants  Participants with adverse events: 152 100.0%"", ""  Participants with serious adverse events: 45  29.6%"", ""  Participants with grade 3 or 4 adverse events: 124  81.6%"", ""  Participants with grade 5 adverse events: 7   4.6%"", ""  Participants discontinued due to adverse events: 9   5.9%""]",Entailment
Patients currently prescribed Diuretics are excluded from NCT01351376.,"[""Exclusion Criteria:"", ""  medication(s) known to affect body fluid balance""]",Entailment
"In contrast to NCT00768222, NCT02102490 did not record any cases of Sinus bradycardia, Bone marrow suppression or Constipation .","[""Adverse Events 1:"", ""  Total: 33/132 (25.00%)"", ""  Febrile neutropenia 1/132 (0.76%)"", ""  Haematotoxicity 1/132 (0.76%)"", ""  Neutropenia 1/132 (0.76%)"", ""  Sinus bradycardia 1/132 (0.76%)"", ""  Tachycardia 1/132 (0.76%)"", ""  Abdominal pain 2/132 (1.52%)"", ""  Abdominal pain upper 1/132 (0.76%)"", ""  Constipation 1/132 (0.76%)"", ""  Large intestinal obstruction 1/132 (0.76%)"", ""  Nausea 3/132 (2.27%)""]",Contradiction
